President and CEO of BioMimetic Therapeutics Inc. (BMTI, Financial) Samuel Eugene Lynch sells 6,000 shares of BMTI on 11/17/2009 at an average price of $11.72 a share.
BioMimetic Therapeutics is a biotech company utilizing recombinant human platelet-derived growth factor (rhPDGF-BB) as its primary technology platform. This molecule is a synthetic copy of one of the body's principal agents to stimulate and direct healing and regeneration. The mechanism of action of this platform technology suggests it may be effective in a broad array of musculoskeletal applications, including the repair of bone, ligament, tendon and cartilage. Through the commercialization of this technology, BioMimetic seeks to become the leading company in the field of orthopedic regenerative medicine. Additionally, BioMimetic Therapeutics has completed and ongoing clinical trials with its product candidates Augment and Augment Injectable in multiple orthopedic bone healing indications including the treatment of foot and ankle fusions and the stimulation of healing of fractures of the wrist. Biomimetic Therapeutics Inc. has a market cap of $250.8 million; its shares were traded at around $11.53 with and P/S ratio of 79.7.
BioMimetic Therapeutics is a biotech company utilizing recombinant human platelet-derived growth factor (rhPDGF-BB) as its primary technology platform. This molecule is a synthetic copy of one of the body's principal agents to stimulate and direct healing and regeneration. The mechanism of action of this platform technology suggests it may be effective in a broad array of musculoskeletal applications, including the repair of bone, ligament, tendon and cartilage. Through the commercialization of this technology, BioMimetic seeks to become the leading company in the field of orthopedic regenerative medicine. Additionally, BioMimetic Therapeutics has completed and ongoing clinical trials with its product candidates Augment and Augment Injectable in multiple orthopedic bone healing indications including the treatment of foot and ankle fusions and the stimulation of healing of fractures of the wrist. Biomimetic Therapeutics Inc. has a market cap of $250.8 million; its shares were traded at around $11.53 with and P/S ratio of 79.7.
Insiders' Positions with BMTI
- Sell:: President and CEO Samuel Eugene Lynch sold 6,000 shares of BMTI stock on 11/05/2009 at the average price of 11.67, the price of the stock has decreased by 1.2% since
- Sell:: President and CEO Samuel Eugene Lynch sold 9,000 shares of BMTI stock on 10/21/2009 at the average price of 14.03, the price of the stock has decreased by 17.82% since
- Sell:: President and CEO Samuel Eugene Lynch sold 7,500 shares of BMTI stock on 10/06/2009 at the average price of 12.14, the price of the stock has decreased by 5.02% since
- Sell:: President and CEO Samuel Eugene Lynch sold 9,000 shares of BMTI stock on 09/24/2009 at the average price of 13.03, the price of the stock has decreased by 11.51% since
- Sell:: President and CEO Samuel Eugene Lynch sold 6,000 shares of BMTI stock on 09/10/2009 at the average price of 12, the price of the stock has decreased by 3.92% since
Insiders' Positions with BMTI
- Buy:: Director James G Murphy bought 508 shares of BMTI stock on 06/25/2009 at the average price of 8.5, the price of the stock has increased by 35.65% since
- Buy:: 10% Owner A/s Novo bought 343,406 shares of BMTI stock on 06/25/2009 at the average price of 8.5, the price of the stock has increased by 35.65% since
- Buy:: Director Gary E Friedlaender bought 8,174 shares of BMTI stock on 06/25/2009 at the average price of 8.5, the price of the stock has increased by 35.65% since
